Lv3
370 积分 2025-11-17 加入
Antibody-Drug Conjugates in Oncology: Why Potency Is No Longer the Limiting Factor
13天前
已关闭
Covalent inhibitors of the RAS binding domain of PI3Kα impair tumor growth driven by RAS and HER2
14天前
已完结
Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain
16天前
已完结
The basis and advances in clinical application of boron neutron capture therapy
20天前
已完结
State-of-the-art boron clusters for boron neutron-capture therapy
20天前
已完结
STX-478, RLY-2608, and LOXO-783: third-generation PIK3CA mutant-selective allosteric inhibitors
21天前
已完结
Targeting XPO1 for fighting relapsed/refractory diseases: The research progress of XPO1 inhibitors
1个月前
已完结
Therapeutic horizons in targeting XPO1 with small inhibitor molecules: Recent achievements, synthetic strategies, opportunities, challenges, and future perspectives
1个月前
已完结
Synergistic Effects of ATR Inhibition and Lurbinectedin in Soft-Tissue Sarcomas: The Predictive Role of SLFN11 Expression
2个月前
已完结
How multispecific molecules are transforming pharmacotherapy
2个月前
已完结
皖公网安备34019202002308
